- Concert Pharmaceuticals has a JAK inhibitor for alopecia areata (AA) that may be superior to competitive products.
- The company cites a figure of 1.5m US patients with AA. Published literature cites a prevalence of 700,000 patients and only 300,000 with moderate to severe AA.
- The first JAK inhibitor is now approved for the treatment of severe AA.
- A key question for investors is what peak sales figure for CTP-543 can investors reasonably expect, and how does that impact the risk/reward.
For further details see:
Concert Pharmaceuticals: A Balanced Risk/Reward